Long-term health outcomes of COVID-19 in ICU- and non-ICU-treated patients up to 2 years after hospitalization: a longitudinal cohort study (CO-FLOW)

期刊论文
出版模式：

开放获取
发表日期：

2024年11月8日

查看全文

J. C. Berentschot,
L. M. Bek,
M. H. Heijenbrok-Kal,
J. van Bommel,
G. M. Ribbers,
J. G. J. V. Aerts,
M. E. Hellemons,
H. J. G. van den Berg-Emons,
Joachim G. J. V. Aerts,
L. Martine Bek,
Julia C. Berentschot,
Rita J. G. van den Berg-Emons,
Sieshem Bindraban,
Wouter J. B. Blox,
Jasper van Bommel,
Shai A. Gajadin,
Michel E. van Genderen,
Diederik A. M. P. J. Gommers,
Majanka H. Heijenbrok-Kal,
Merel E. Hellemons,
Roxane Heller,
Erwin Ista,
Stephanie van Loon-Kooij,
Chantal Luijkx,
Rutger Osterthun,
Laurien Oswald,
Gerard M. Ribbers,
Ronald N. van Rossem,
Herbert J. van de Sande,
Robert van der Stoep,
Janette J. Tazmi-Staal,
Markus P. J. M. Wijffels,
Eva G. Willems

摘要

Background

Many patients hospitalized for COVID-19 experience long-term health problems, but comprehensive longitudinal data up to 2 years remain limited. We aimed to (1) assess 2-year trajectories of health outcomes, including comparison between intensive care unit (ICU) treated and non-ICU-treated patients, and (2) identify risk factors for prominent health problems post-hospitalization for COVID-19.

Methods

The CO-FLOW multicenter prospective cohort study followed adults hospitalized for COVID-19 at 3, 6, 12, and 24 months post-discharge. Measurements included patient-reported outcomes (a.o., recovery, symptoms, fatigue, mental health, sleep quality, return to work, health-related quality of life [HRQoL]), and objective cognitive and physical tests. Additionally, routine follow-up data were collected.

Results

650 patients (median age 60.0 [IQR 53.0–67.0] years; 449/650 [69%] male) surviving hospitalization for COVID-19 were included, of whom 273/650 (42%) received ICU treatment. Overall, outcomes improved over time. Nonetheless, 73% (322/443) of patients had not completely recovered from COVID-19, with memory problems (274/443; 55%), concentration problems (259/443; 52%), and dyspnea (251/493; 51%) among most frequently reported symptoms at 2 years. Moreover, 61% (259/427) had poor sleep quality, 51% (222/433) fatigue, 23% (102/438) cognitive failures, and 30% (65/216) did not fully return to work. Objective outcome measures showed generally good physical recovery. Most outcomes were comparable between ICU- and non-ICU-treated patients at 2 years. However, ICU-treated patients tended to show slower recovery in neurocognitive symptoms, mental health outcomes, and resuming work than non-ICU-treated patients, while showing more improvements in physical outcomes. Particularly, female sex and/or pre-existing pulmonary disease were major risk factors for poorer outcomes.

Conclusions

73% (322/443) of patients had not completely recovered from COVID-19 by 2 years. Despite good physical recovery, long-term neurocognitive complaints, dyspnea, fatigue, and impaired sleep quality persisted. ICU-treated patients showed slower recovery in neurocognitive and mental health outcomes and resumption of work. Tailoring long-term COVID-19 aftercare to individual residual needs is essential. Follow-up is required to monitor further recovery.

Trial registration: NL8710, registration date 12-06-2020.